Across TCGA pan-cancer cohorts, RAD54B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RAD54B data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RAD54B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RAD54B expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where RAD54B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	II,III,IV	0.867	0.396	.015	4	view →
LSCC	DFS	Tertile	II,III,IV	0.486	0.815	.029	3	view →
LUAD	OS	Median	II,III,IV	1.000	0.700	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: RAD54B tumor-vs-normal RNA expression · all RAD54B data types